Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 17, 2026 02:10 ET | Source: Boehringer Ingelheim

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU

Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic...
July 16, 2026 01:00 ET | Source: Boehringer Ingelheim

Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development

Not intended for UK and US audiencesBoehringer Ingelheim announces the start of a Phase II clinical trial evaluating the efficacy and safety of its novel triple receptor agonist, BI 3034701, in people...
July 15, 2026 01:36 ET | Source: Boehringer Ingelheim

Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.

Strong U.S. demand and new product launches drive first-half sales in Human PharmaNet sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launchesPositive Phase III data for...
June 22, 2026 03:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers

Boehringer Ingelheim is committed to improving outcomes for people facing aggressive cancers where there are currently few treatment optionsDAREON®-Lung-1 and DAREON®-NEC-1 will evaluate obrixtamig as...
June 18, 2026 04:05 ET | Source: Boehringer Ingelheim Limited

New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF

Not intended for UK and US audiences Nerandomilast long-term survival modeling presented at American Thoracic Society (ATS) 2026 and European Alliance of Associations for Rheumatology (EULAR) 2026...
June 07, 2026 14:30 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel...
May 25, 2026 03:00 ET | Source: Boehringer Ingelheim Limited

The hidden impact of veterinary care: new insights from a global survey of veterinarians

Animal owners may think they know what happens during a veterinary visit — but a new global survey of 1,000+ veterinarians across 51 countries shows there is far more going on than meets the...
May 22, 2026 08:15 ET | Source: Boehringer Ingelheim Limited

CHMP issues positive opinion for JASCAYD® (nerandomilast), bringing a new IPF and PPF therapy closer to patients in the EU

Not intended for US and UK media Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive lung conditions that require early and sustained...
May 22, 2026 03:45 ET | Source: Boehringer Ingelheim Limited

China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis

Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients1Expedited...
May 21, 2026 17:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...